Theravance Biopharma, Inc. (TBPH)
| Market Cap | 884.18M +26.5% |
| Revenue (ttm) | 104.31M +35.1% |
| Net Income | 53.81M +312.9% |
| EPS | 1.05 +300.8% |
| Shares Out | 51.92M |
| PE Ratio | 16.30 |
| Forward PE | 8.41 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 10,043,494 |
| Open | 17.06 |
| Previous Close | 17.03 |
| Day's Range | 17.02 - 17.07 |
| 52-Week Range | 13.08 - 21.03 |
| Beta | 0.24 |
| Analysts | n/a |
| Price Target | n/a |
| Est. Earnings | Nov 9, 2026 |
About TBPH
Theravance Biopharma, Inc., a biopharmaceutical company, develops and commercializes medicines in the United States. It offers YUPELRI, an once-daily, nebulized long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary disease (COPD); and Ampreloxetine an investigational, once-daily norepinephrine reuptake inhibitor, Which is in Phase 3 clinical trials for symptomatic neurogenic orthostatic hypotension (nOH) in patients with Multiple System Atrophy (MSA). It has a strategic collaboration agreement with Viatris Inc. fo... [Read more]
Financial Performance
Financial StatementsNews
Theravance Biopharma Proxy statement: Proxy filing
Theravance Biopharma filed a proxy statement on August 25, 2026, providing details for shareholder voting and corporate governance matters.
Theravance Biopharma Proxy statement: Proxy filing
Theravance Biopharma filed a proxy statement on August 21, 2026, providing details for shareholder voting and corporate governance matters.
Theravance Biopharma Proxy statement: Proxy filing
Theravance Biopharma filed a proxy statement on August 11, 2026, providing details for shareholder voting and corporate governance matters.
Theravance Biopharma, Inc. Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Previously announced acquisition by Zymeworks expected to close in second half of 2026 YUPELRI ® Collaboration Revenue increased 11% year-over-year 1, from $18.7 million to $20.7 million, driven by co...
Theravance Biopharma Earnings release: Q2 2026
Theravance Biopharma released its Q2 2026 earnings on August 10, 2026, summarizing the period's financial results.
Theravance Biopharma Quarterly report: Q2 2026
Theravance Biopharma has published its Q2 2026 quarterly earnings report on August 10, 2026.
Theravance Biopharma Proxy statement: Proxy filing
Theravance Biopharma filed a proxy statement on June 29, 2026, providing details for shareholder voting and corporate governance matters.
Why This Biotech Stock Is Falling After a $929 Million Buyout Lifeline
Theravance Biopharma strikes a deal with Zymeworks to be acquired for $17 a share.
Zymeworks strikes $929 million deal for Theravance Biopharma
Drugmaker Zymeworks said on Monday it will buy Theravance Biopharma in a $929 million deal.
THERAVANCE BIOPHARMA ENTERS INTO DEFINITIVE AGREEMENT TO BE ACQUIRED BY ZYMEWORKS FOR $17.00 PER SHARE IN CASH PLUS A CONTINGENT VALUE RIGHT
Theravance Biopharma shareholders to receive $17.00 per share in cash, representing an equity value of approximately $929 million Theravance Biopharma shareholders to receive a contingent value right ...
Theravance Biopharma Earnings release: Q1 2026
Theravance Biopharma released its Q1 2026 earnings on May 7, 2026, summarizing the period's financial results.
Theravance Biopharma Quarterly report: Q1 2026
Theravance Biopharma has published its Q1 2026 quarterly earnings report on May 7, 2026.
Theravance Biopharma, Inc. Reports First Quarter 2026 Financial Results and Provides Corporate Update
YUPELRI ® Collaboration Revenue increased 15% year-over-year 1 , from $15.4 million to $17.7 million, driven by continued Net Sales growth and improved operating leverage All Hatch-Waxman litigation r...
Theravance Biopharma Proxy statement: Proxy filing
Theravance Biopharma filed a proxy statement on April 28, 2026, providing details for shareholder voting and corporate governance matters.
Theravance Biopharma, Inc. Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
Organizational restructuring and cost reduction plan following results of the Phase 3 CYPRESS study of ampreloxetine are underway; expected to generate $60 - $70 million of annualized cash flow starti...
Theravance Biopharma Annual report: Q4 2025
Theravance Biopharma has published its Q4 2025 annual report on March 19, 2026.
Theravance Biopharma Earnings release: Q4 2025
Theravance Biopharma released its Q4 2025 earnings on March 19, 2026, summarizing the period's financial results.
Theravance Biopharma Slides: Corporate presentation
Theravance Biopharma has posted slides in relation to its latest quarterly earnings report, which was published on March 7, 2026.
Theravance plans strategic review, including possible sale, after drug trial failure
Theravance Biopharma said on Tuesday it is initiating a strategic review, including a possible sale of the company, after its experimental drug to treat a type of blood pressure disorder failed to...
Theravance Biopharma Reports Phase 3 CYPRESS Study Did Not Meet Primary Endpoint; Board Accelerates Strategic Review and Announces Cost Reduction Actions
Phase 3 CYPRESS study did not meet the primary endpoint , the OHSA Composite Score, a patient reported outcome (PRO) Cash of $326.5 million at Q4 2025 (no debt); approximately $400 million expected at...
Theravance Biopharma Transcript: KOL Event
Ampreloxetine is positioned as a first-in-class, once-daily therapy for NOH in MSA, addressing a major unmet need with durable efficacy and a favorable safety profile. The pivotal Cypress phase III study is designed with FDA alignment, and commercial strategy targets a concentrated specialist market, supporting rapid adoption and premium pricing if approved.
Theravance Biopharma Slides: KOL Event
Theravance Biopharma has posted slides in relation to its latest quarterly earnings report, which was published on December 8, 2025.
Theravance Biopharma Transcript: Evercore ISI 8th Annual HealthCONx Conference
The business is now focused on maximizing cash flow from Yupelri and advancing ampreloxetine for MSA-related nOH, with a pivotal Phase 3 readout expected in Q1. Strong financials, positive payer feedback, and robust clinical data position the company for potential NDA submission and commercial success.
Theravance Biopharma to Host Virtual KOL Investor Event to Review Ampreloxetine Phase 3 Clinical Development Program, Ahead of Topline Data in Q1 2026, on December 8, 2025
DUBLIN , Nov. 20, 2025 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) today announced that it will host a virtual key opinion leader (KOL) investor event on Monday, December 8, 2025 at 10:3...
Theravance Biopharma Slides: Corporate Presentation
Theravance Biopharma has posted slides in relation to its latest quarterly earnings report, which was published on November 20, 2025.